Humacyte (HUMA) Revenue & Revenue Breakdown
Humacyte Revenue Highlights
0
Latest Revenue (Q)
$301.00K
Humacyte Revenue by Period
Humacyte Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $1.56M | 23.91% |
| 2021-12-31 | $1.26M | -15.29% |
| 2020-12-31 | $1.49M | -75.90% |
| 2019-12-31 | $6.19M | - |
Humacyte generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Humacyte Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $301.00K | -41.78% |
| 2025-03-31 | $517.00K | -92.85% |
| 2024-12-31 | $7.23M | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $10.79M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | -100.00% |
| 2022-09-30 | $31.00K | -97.62% |
| 2022-06-30 | $1.30M | 458.37% |
| 2022-03-31 | $233.00K | 31.64% |
| 2021-12-31 | $177.00K | -26.56% |
| 2021-09-30 | $241.00K | -65.07% |
| 2021-06-30 | $690.00K | 345.16% |
| 2021-03-31 | $155.00K | 25.00% |
| 2020-12-31 | $124.00K | -86.43% |
| 2020-09-30 | $914.00K | 361.62% |
| 2020-06-30 | $198.00K | -22.35% |
| 2020-03-31 | $255.00K | - |
Humacyte generated $301.00K in revenue during Q2 2025, up -41.78% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Humacyte Revenue Breakdown
Humacyte Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Jun 25 | Mar 25 | Sep 21 |
|---|---|---|---|
| Product and Service, Other | $201.00K | $370.00K | - |
| Product | $100.00K | $147.00K | - |
| Reimbursement of certain allowable costs related to grants | - | - | $200.00K |
Latest
Humacyte's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Product and Service, Other (66.78%), and Product (33.22%).
Humacyte Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Sep 21 |
|---|---|
| Reimbursement of certain allowable costs related to grants | $200.00K |
Latest
Humacyte's latest quarterly revenue breakdown by geography, as of Sep 21: Reimbursement of certain allowable costs related to grants (100.00%).
Humacyte Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals | $423.24M | $156.80M |
| GLUE | Monte Rosa Therapeutics | $75.62M | $84.93M |
| IDYA | IDEAYA Biosciences | $7.00M | - |
| ABSI | Absci | $4.53M | $593.00K |
| QSI | Quantum-Si | $3.06M | $591.00K |
| COGT | Cogent Biosciences | - | - |
| CRBU | Caribou Biosciences | - | - |
| HUMA | Humacyte | - | $301.00K |
| NAUT | Nautilus Bio | - | - |